DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation

Case Reports in Medicine

Volumn 2016, Issue , 2016, Pages

  Dhakal, B ^a   D'Souza, A ^a   Pasquini, M ^a   Saber, W ^a   Fenske, T S ^a   Moss, R B ^b   Drobyski, W R ^a   Hari, P ^a   Abidi, M Z ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Ansun BioPharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; DAS 181; GANCICLOVIR; RIBAVIRIN; SIALIDASE; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CASE REPORT; CAUCASIAN; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN PARAINFLUENZA VIRUS 3; LABORATORY TEST; LUNG LAVAGE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEIC ACID AMPLIFICATION; OXYGEN CONSUMPTION; OXYGEN SATURATION; PARAMYXOVIRUS INFECTION; PNEUMOCOCCAL INFECTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; TREATMENT DURATION; VIRUS PNEUMONIA;

EID: 85011094757     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2016/8503275     Document Type: Article

References (16)

1. M. Boeckh, "The challenge of respiratory virus infections in hematopoietic cell transplant recipients," British Journal of Haematology, vol. 143, no. 4, pp. 455-467, 2008.
2. C. B. Hall, "Respiratory syncytial virus and parainfluenza virus," The New England Journal of Medicine, vol. 344, no. 25, pp. 1917-1928, 2001.
3. C. Renaud and A. P. Campbell, "Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients," Current Opinion in Infectious Diseases, vol. 24, no. 4, pp. 333-343, 2011.
4. J. Englund, T. Feuchtinger, and P. Ljungman, "Viral infections in immunocompromised patients," Biology of Blood and Marrow Transplantation, vol. 17, no. 1, supplement, pp. S2-S5, 2011.
5. W. Garrett Nichols, L. Corey, T. Gooley, C. Davis, and M. Boeckh, "Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome," Blood, vol. 98, no. 3, pp. 573-578, 2001.
6. M. P. Malakhov, L. M. Aschenbrenner, D. F. Smee et al., "Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection," Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1470-1479, 2006.
7. R. B. Moss, C. Hansen, R. L. Sanders, S. Hawley, T. Li, and R. T. Steigbigel, "A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection," The Journal of Infectious Diseases, vol. 206, no. 12, pp. 1844-1851, 2012.
8. B. G. Jones, R. T. Hayden, and J. L. Hurwitz, "Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model," Antiviral Research, vol. 100, no. 2, pp. 562-566, 2013.
9. A. Moscona, M. Porotto, S. Palmer et al., "A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo," The Journal of Infectious Diseases, vol. 202, no. 2, pp. 234-241, 2010.
10. S. Chalkias, M. R. Mackenzie, C. Gay et al.,"DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation," Transplant Infectious Disease, vol. 16, no. 1, pp. 141-144, 2014.
11. Y.-B. Chen, J. P. Driscoll, S. L. McAfee et al., "Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation," Clinical Infectious Diseases, vol. 53, no. 7, pp. e77-e80, 2011.
12. D. R. Drozd, A. P. Limaye, R. B. Moss et al., "DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient," Transplant Infectious Disease, vol. 15, no. 1, pp. E28-E32, 2013.
13. B. B. Guzmán-Suarez, M. W. Buckley, E. T. Gilmore et al., "Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients," Transplant Infectious Disease, vol. 14, no. 4, pp. 427-433, 2012.
14. A. Waghmare, T. Wagner, R. Andrews et al., "Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children," Journal of the Pediatric Infectious Diseases Society, vol. 4, no. 2, pp. 114-118, 2015.
15. R. F. Chemaly, S. S. Hanmod, D. B. Rathod et al., "The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation," Blood, vol. 119, no. 12, pp. 2738-2745, 2012.
16. S. Seo, H. Xie, A. P. Campbell et al., "Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome," Clinical Infectious Diseases, vol. 58, no. 10, pp. 1357-1368, 2014.